Related Experiment Video
Updated: May 26, 2026
10:58
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Brain metastases from ovarian carcinoma
1Department of Obstetrics and Gynecology, Sapir Medical Center, Sackler School of Medicine, University of Tel-Aviv, Kfar-Saba 44281, Israel.
ISRN Oncology
|December 23, 2011
Summary
Brain metastases are rare in ovarian carcinoma but often indicate advanced disease. Multimodal therapy significantly improves survival compared to whole brain radiotherapy alone.
Area of Science:
- Oncology
- Neurology
- Gynecologic Oncology
Background:
- Brain metastases from ovarian carcinoma are infrequent, documented in less than 600 cases.
- Incidence ranges from 0.29% to 11.6% in ovarian carcinoma patients.
- Typically associated with advanced-stage epithelial serous carcinoma.
Purpose of the Study:
- To review current knowledge on brain metastases in ovarian carcinoma.
- To analyze incidence, clinical characteristics, treatment evolution, and survival outcomes.
- To provide recommendations for patient follow-up.
Main Methods:
- Literature review of documented cases.
- Analysis of incidence rates and patient demographics.
- Comparison of treatment modalities and survival data.
Main Results:
- Median interval from ovarian carcinoma diagnosis to brain metastases is 2 years.
- Metastases are often multiple, affect the cerebrum, and are part of disseminated disease.
- Multimodal therapy (surgery, radiosurgery, WBRT, chemotherapy) shows improved survival over WBRT alone.
Conclusions:
- Multimodal therapy significantly enhances survival for ovarian carcinoma patients with brain metastases.
- Routine brain imaging during follow-up is recommended for ovarian carcinoma patients.
- Further research into optimal management strategies is warranted.
